Baidu
map

大麻药物治疗亨廷顿病的IND申请

2018-08-05 MedSci MedSci原创

MMJ国际控股公司是目前通过患者临床研究推进医用大麻科学的首屈一指的医学科研公司,2018年8月4日宣布已向美国食品药品监督管理局(FDA)提交了一份研究前新药(IND)申请,以开始治疗与亨廷顿病相关的临床试验。MMJ正在寻求FDA的许可,以开发一种源自大麻植物天然提取物的医药级大麻药物。MMJ的主要医学研究人员将进行首次临床试验,以调查和证明其天然植物大麻提取物专有配方作为亨廷顿病治疗的功效。

MMJ国际控股公司是目前通过患者临床研究推进医用大麻科学的首屈一指的医学科研公司,201884日宣布已向美国食品药品监督管理局(FDA)提交了一份研究前新药(IND)申请,以开始治疗与亨廷顿病相关的临床试验。MMJ正在寻求FDA的许可,以开发一种源自大麻植物天然提取物的医药级大麻药物。MMJ的主要医学研究人员将进行首次临床试验,以调查和证明其天然植物大麻提取物专有配方作为亨廷顿病治疗的功效。

亨廷顿病(HuntingtondiseaseHD)又称亨廷顿舞蹈病、慢性进行性舞蹈病、遗传性舞蹈病,于1842年由Waters首报,1872年由美国医生GeorgeHuntington系统描述而得名,是一种常染色体显性遗传的基底节和大脑皮质变性疾病,临床上以隐匿起病、缓慢进展的舞蹈症、精神异常和痴呆为特征。本病呈完全外显,受累个体的后代患病概率为50%,可发生于所有人种,白种人发病率最高,中国则较少见。


原始出处:

http://www.firstwordpharma.com/node/1583102#axzz5NCMJrdAy

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1272734, encodeId=687812e27341b, content=<a href='/topic/show?id=d04f440581e' target=_blank style='color:#2F92EE;'>#大麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44058, encryptionId=d04f440581e, topicName=大麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Tue Aug 07 03:19:00 CST 2018, time=2018-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365107, encodeId=60d1136510e47, content=<a href='/topic/show?id=c83a2455270' target=_blank style='color:#2F92EE;'>#亨廷顿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24552, encryptionId=c83a2455270, topicName=亨廷顿病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Aug 07 03:19:00 CST 2018, time=2018-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469117, encodeId=97eb146911e29, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Tue Aug 07 03:19:00 CST 2018, time=2018-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622764, encodeId=af201622e6470, content=<a href='/topic/show?id=4a6e2454879' target=_blank style='color:#2F92EE;'>#亨廷顿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24548, encryptionId=4a6e2454879, topicName=亨廷顿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Aug 07 03:19:00 CST 2018, time=2018-08-07, status=1, ipAttribution=)]
    2018-08-07 kcb069
  2. [GetPortalCommentsPageByObjectIdResponse(id=1272734, encodeId=687812e27341b, content=<a href='/topic/show?id=d04f440581e' target=_blank style='color:#2F92EE;'>#大麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44058, encryptionId=d04f440581e, topicName=大麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Tue Aug 07 03:19:00 CST 2018, time=2018-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365107, encodeId=60d1136510e47, content=<a href='/topic/show?id=c83a2455270' target=_blank style='color:#2F92EE;'>#亨廷顿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24552, encryptionId=c83a2455270, topicName=亨廷顿病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Aug 07 03:19:00 CST 2018, time=2018-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469117, encodeId=97eb146911e29, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Tue Aug 07 03:19:00 CST 2018, time=2018-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622764, encodeId=af201622e6470, content=<a href='/topic/show?id=4a6e2454879' target=_blank style='color:#2F92EE;'>#亨廷顿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24548, encryptionId=4a6e2454879, topicName=亨廷顿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Aug 07 03:19:00 CST 2018, time=2018-08-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1272734, encodeId=687812e27341b, content=<a href='/topic/show?id=d04f440581e' target=_blank style='color:#2F92EE;'>#大麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44058, encryptionId=d04f440581e, topicName=大麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Tue Aug 07 03:19:00 CST 2018, time=2018-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365107, encodeId=60d1136510e47, content=<a href='/topic/show?id=c83a2455270' target=_blank style='color:#2F92EE;'>#亨廷顿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24552, encryptionId=c83a2455270, topicName=亨廷顿病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Aug 07 03:19:00 CST 2018, time=2018-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469117, encodeId=97eb146911e29, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Tue Aug 07 03:19:00 CST 2018, time=2018-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622764, encodeId=af201622e6470, content=<a href='/topic/show?id=4a6e2454879' target=_blank style='color:#2F92EE;'>#亨廷顿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24548, encryptionId=4a6e2454879, topicName=亨廷顿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Aug 07 03:19:00 CST 2018, time=2018-08-07, status=1, ipAttribution=)]
    2018-08-07 xiaogang319
  4. [GetPortalCommentsPageByObjectIdResponse(id=1272734, encodeId=687812e27341b, content=<a href='/topic/show?id=d04f440581e' target=_blank style='color:#2F92EE;'>#大麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44058, encryptionId=d04f440581e, topicName=大麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Tue Aug 07 03:19:00 CST 2018, time=2018-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365107, encodeId=60d1136510e47, content=<a href='/topic/show?id=c83a2455270' target=_blank style='color:#2F92EE;'>#亨廷顿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24552, encryptionId=c83a2455270, topicName=亨廷顿病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Aug 07 03:19:00 CST 2018, time=2018-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469117, encodeId=97eb146911e29, content=<a href='/topic/show?id=211f98250b' target=_blank style='color:#2F92EE;'>#IND#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9825, encryptionId=211f98250b, topicName=IND)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=16377007930, createdName=xiaogang319, createdTime=Tue Aug 07 03:19:00 CST 2018, time=2018-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622764, encodeId=af201622e6470, content=<a href='/topic/show?id=4a6e2454879' target=_blank style='color:#2F92EE;'>#亨廷顿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24548, encryptionId=4a6e2454879, topicName=亨廷顿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Aug 07 03:19:00 CST 2018, time=2018-08-07, status=1, ipAttribution=)]

相关资讯

大麻有助于减少Lennox-Gastaut综合征的癫痫发作

一项III期随机临床试验证明,大麻二酚的药物制剂联合其他抗癫痫药物有助于减少对先前治疗无反应的Lennox-Gastaut综合征患者的癫痫发作次数,包括由于肌张力突然减退而引发的癫痫发作。

FDA批准GW制药的Epidiolex用于治疗癫痫

FDA批准GW制药的Epidiolex标志着美国首次批准大麻素衍生药物。GW制药表示,FDA批准Epidiolex(cannabidiol)口服溶液治疗与Lennox-Gastaut综合征或Dravet综合征有关的癫痫发作

JACC:可卡因和大麻的使用可增加心梗患者死亡风险!

化学品滥用现象在青少年中越来越普遍,但其与心血管疾病发生的关系尚属未知。本研究的目的旨在评估年龄≤50岁出现有心梗成年人中可卡因和大麻的使用情况及其与远期预后的关系。本研究纳入分析了来自2家学术型医院2000-2016年诊断为1型心梗的患者,最终共纳入了2097名1型心梗患者(平均年龄44.0 ± 5.1岁,女性占19.3%,白种人占73%),平均随访时间是11.2年。分析结果显示,有224名患者

大麻外用药膏用于治疗女性性欲望障碍

Pivot制药公司近日宣布,将向美国食品和药物管理局(FDA)提交一份研究性新药(IND)申请,并与加拿大卫生部合作,开始对Pivot制药的候选药物PVT-005进行人体临床试验,用于治疗女性性欲望障碍(HSDD)。

Lancet Public Health :澳研究称医用大麻不一定能减轻慢性非癌性疼痛

澳大利亚研究人员在最新一期英国《柳叶刀·公共卫生》上发表报告称,医用大麻不一定能减轻慢性非癌性疼痛。

Eur J Intern Med:大麻改善晚期癌症患者生存质量:真相究竟是什么?

2018年3月《European Journal of Internal Medicine》欧洲内科医学杂志最新发表的文章“大型前瞻性研究——医用大麻在癌症人群中的安全性和疗效” ,首次证实了几十年来关于大麻在癌症患者中的获益,大麻对癌症患者可能是安全有效的姑息治疗。

Baidu
map
Baidu
map
Baidu
map